Premium
Changes in protein serum levels during stem cell transplantation
Author(s) -
Metafuni Elisabetta,
Giammarco Sabrina,
De Ritis Daniela Giovanna,
Rossi Monica,
Corrente Francesco,
Piccirillo Nicola,
Bacigalupo Andrea Paolo,
Sica Simona,
Chiusolo Patrizia
Publication year - 2017
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12796
Subject(s) - medicine , hematopoietic stem cell transplantation , elafin , b cell activating factor , cohort , immunology , transplantation , stem cell , gastroenterology , b cell , biology , antibody , genetics
Background GvHD is one of the major complication after stem cell transplantation affecting transplant‐related mortality. Throughout the last years, many serum proteins were been proposed as possible biomarkers for GvHD. Aims We studied the trend of five of the most studied serum proteins to evaluate whether a correlation exists between proteins concentration and post‐HSCT outcomes. Materials and methods We measured serum concentration of REG3α, ST2, B‐cell activating factor (BAFF), CXCL9 and elafin in a cohort of 77 patients submitted to Hematopoietic allogeneic stem cell transplantation (HSCT) in our department. Blood samples were been collected at baseline, day +30, GvHD onset and GvHD resolution. Results REG3α levels showed an association only with acute GvHD. Elafin and ST2 levels varied according to both acute and chronic GvHD occurrence. BAFF concentration showed an inverse association with acute GvHD development. Interestingly, baseline BAFF and ST2 levels predicted post‐HSCT survival. No associations were found for CXCL9. Conclusions Except for CXCL9, the protein levels seem to change according to GvHD development, independently from organ involvement and grading. Pretransplant ST2 and BAFF appeared to be predictors for survival after HSCT.